Improved biopharmaceutical properties of carvedilol employing α-tocopheryl polyethylene glycol 1000 succinate-based self-emulsifying drug delivery system

References

• Hamdy N, El-demerdash E. New therapeutic aspect for carvedilol: anti fibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage. Toxicol Appl Pharmacol. 2012;261:292–299.
   PubMed Web of Science ®Google Scholar
• Onoue S, Nakamura T, Uchida A, et al. Physicochemical and biopharmaceutical characterization of amorphous solid dispersion of nobiletin, a citrus polymethoxylated flavone, with improved hepatoprotective effects. Eur J Pharm Sci. 2013;49:453–460.
   PubMed Web of Science ®Google Scholar
• De Araújo RF, Garcia VB, De Carvalho Leitão RF, et al. Carvedilol improves inflammatory response, oxidative stress and fibrosis in the alcohol-induced liver injury in rats by regulating kuppfer cells and hepatic stellate cells. PLoS One. 2016;11:1–23.
   Web of Science ®Google Scholar
• de Meijer VE, Sverdlov DY, Popov Y, et al. Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. PLoS One. 2010;5:e11256.
   PubMed Web of Science ®Google Scholar
• Linton SD. Caspase inhibitors: a pharmaceutical industry perspective. Curr Top Med Chem. 2005;5:1697–1717.
   PubMed Web of Science ®Google Scholar
• Sepodes B, Maio R, Pinto R, et al. Tempol, an intracelullar free radical scavenger, reduces liver injury in hepatic ischemia-reperfusion in the rat. Transplant Proc. 2004;36:849–853.
   PubMed Web of Science ®Google Scholar
• Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology. 2010;51:2214–2218.
   PubMed Web of Science ®Google Scholar
• Al-Rajaie SS. Inhibition of ethanol-induced gastric mucosal damage by carvedilol in male Wistar albino rats: possible biochemical changes. Int J Pharmacol. 2009;5:146–154.
   Google Scholar
• Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. 1994;26:335–346.
   Google Scholar
• Book WM. Carvedilol: a nonselective beta blocking agent with antioxidant properties. Congest Heart Fail. 2002;8:173–177, 190.
   PubMedGoogle Scholar
• Colucci WS, Packer M, Bristow MR, et al. Carvedilol Inhibits Clinical Progression in Patients With Mild Symptoms of Heart Failure. Circulation. 1996;94:2800–2806.
   PubMed Web of Science ®Google Scholar
• Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens. 2007;25:731–741.
   PubMed Web of Science ®Google Scholar
• Hamed R, Awadallah A, Sunoqrot S, et al. pH-Dependent solubility and dissolution behavior of carvedilol—case example of a weakly basic BCS class II drug. AAPS PharmSciTech. 2016;17:418–426.
   PubMed Web of Science ®Google Scholar
• Hong JY, Kim JK, Song YK, et al. A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J Control Release. 2006;110:332–338.
   PubMed Web of Science ®Google Scholar
• Neugebauer G, Akpan W, Kaufmann B, et al. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur J Clin Pharmacol. 1990;38:108–111.
   PubMed Web of Science ®Google Scholar
• Mahmoud EA, Bendas ER, Mohamed MI. Preparation and evaluation of self-nanoemulsifying tablets of carvedilol. AAPS PharmSciTech. 2009;10:183–192.
   PubMed Web of Science ®Google Scholar
• Giessmann T, Modess C, Hecker U, et al. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther. 2004;75:213–222.
   PubMed Web of Science ®Google Scholar
• Pokharkar V, Khanna A, Venkatpurwar V, et al. Ternary complexation of carvedilol, beta-cyclodextrin and citric acid for mouth-dissolving tablet formulation. Acta Pharm. 2009;59:121–132.
   PubMed Web of Science ®Google Scholar
• Hirlekar R, Kadam V. Preparation and characterization of inclusion complexes of carvedilol with methyl-β-cyclodextrin. J Incl Phenom Macrocycl Chem. 2009;63:219–224.
   Web of Science ®Google Scholar
• Wei L, Sun P, Nie S, et al. Preparation and evaluation of SEDDS and SMEDDS containing carvedilol. Drug Dev Ind Pharm. 2005;31:785–794.
   PubMed Web of Science ®Google Scholar
• Liu D, Xu H, Tian B, et al. Fabrication of carvedilol nanosuspensions through the anti-solvent precipitation-ultrasonication method for the improvement of dissolution rate and oral bioavailability. AAPS PharmSciTech. 2012;13:295–304.
   PubMed Web of Science ®Google Scholar
• Venishetty VK, Chede R, Komuravelli R, et al. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration. Colloids Surfaces B Biointerfaces. 2012;95:1–9.
   PubMed Web of Science ®Google Scholar
• Planinšek O, Kovačič B, Vrečer F. Carvedilol dissolution improvement by preparation of solid dispersions with porous silica. Int J Pharm. 2011;406:41–48.
   PubMed Web of Science ®Google Scholar
• Potluri RHK, Bandari S, Jukanti R, et al. Solubility enhancement and physicochemical characterization of carvedilol solid dispersion with Gelucire 50/13. Arch Pharm Res. 2011;34:51–57.
   PubMed Web of Science ®Google Scholar
• Shamma RN, Basha M. Soluplus: a novel polymeric solubilizer for optimization of carvedilol solid dispersions: formulation design and effect of method of preparation. Powder Technol. 2013;237:406–414.
   Web of Science ®Google Scholar
• Sharma A, Jain CP. Preparation and characterization of solid dispersions of carvedilol with PVP K30. Res Pharm Sci. 2010;5:45–52.
   Google Scholar
• De Smidt PC, Campanero MA, Trocóniz IF. Intestinal absorption of penclomedine from lipid vehicles in the conscious rat: contribution of emulsification versus digestibility. Int J Pharm. 2004;270:109–118.
   Google Scholar
• Constantinides PP, Wasan KM. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. J Pharm Sci. 2007. 235–248.
   PubMed Web of Science ®Google Scholar
• Pouton CW, Porter CJH. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev. 2008;60:625–637.
   PubMed Web of Science ®Google Scholar
• Kohli K, Chopra S, Dhar D, et al. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov Today. 2010;15:958–965.
   PubMed Web of Science ®Google Scholar
• Reintjes T. 10. KolliphorTM P grades (Poloxamers). Solubility enhanc. with BASF pharma polym. Solubilizer Compend. 2011;103–111.
   Google Scholar
• Qi Y, Qin X, Yang C, et al. Micelle system based on molecular economy principle for overcoming multidrug resistance and inhibiting metastasis. Mol Pharm. 2018;15:1005–1016.
   PubMed Web of Science ®Google Scholar
• Bergmeyer HU, Scheibe P, Wahlefeld AW. Optimization of methods for aspartate aminotransferase and alanine aminotransferase. Clin Chem. 1978;24:58–73.
   PubMed Web of Science ®Google Scholar
• Porter CJH, Pouton CW, Cuine JF, et al. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev. 2008;60:673–691.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S. Review article DLS and zeta potential – What they are and what they are not? J Control Release. 2016;235:337–351.
   PubMed Web of Science ®Google Scholar
• Halder S, Tabata A, Seto Y, et al. Amorphous solid dispersions of carvedilol along with pH-modifiers improved pharmacokinetic properties under hypochlorhydoria. Biopharm Drug Dispos. 2018;39:232–242.
   PubMed Web of Science ®Google Scholar
• Balakrishnan P, Lee B, Hoon D, et al. Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS). Eur J Pharm Biopharm. 2009;72:539–545.
   PubMed Web of Science ®Google Scholar
• Yang C, Wu T, Qi Y, et al. Recent advances in the application of vitamin E TPGS for drug delivery. Theranostics. 2018;8:464–485.
   PubMed Web of Science ®Google Scholar
• Hayashi S, Itoh A, Isoda K, et al. Fucoidan partly prevents CCl4-induced liver fibrosis. Eur J Pharmacol. 2008;580:380–384.
   PubMed Web of Science ®Google Scholar
• Goeptar a R, Scheerens H, Vermeulen NP. Oxygen and xenobiotic reductase activities of cytochrome P450. Crit Rev Toxicol. 1995;25:25–65.
   PubMed Web of Science ®Google Scholar
• Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol. 2010;7:425–436.
   PubMed Web of Science ®Google Scholar
• Dandona P, Karne R, Ghanim H, et al. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids [In Process Citation]. Circulation. 2000;101:122–124.
   PubMed Web of Science ®Google Scholar
• Forrest EH, Bouchier IAD, Hayes PC. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis. J Hepatol. 1996;25:909–915.
   PubMed Web of Science ®Google Scholar
• Vailati MDCF, Rocha NS, Matsubara LS, et al. Protective effects of carvedilol on systemic vascular damage induced by angiotensin II: organ-specific effects independent of antihypertensive effects. Med. Sci. Monit. 2010;16:BR6–BR10.
   PubMed Web of Science ®Google Scholar